Can a fixed drug eruption cause blister-like lesions?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 17, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Yes, Fixed Drug Eruption Can Cause Blister-Like Lesions

Fixed drug eruption (FDE) can absolutely cause blister-like lesions, particularly in its bullous variant, which represents a severe form of this cutaneous adverse reaction.

Clinical Presentation of Bullous FDE

FDE typically presents as recurrent, well-demarcated erythematous or violaceous patches that appear at the same anatomical site with each drug re-exposure. However, bullous lesions are a well-recognized manifestation, occurring in approximately 26.7% of genital FDE cases 1 and representing a distinct severe variant when generalized.

Generalized Bullous Fixed Drug Eruption (GBFDE)

GBFDE is a severe cutaneous adverse reaction characterized by widespread plaques with bullae 2. Key features include:

  • Rapid onset: Median latency of only 24 hours (IQR 12-72 hours) after drug exposure 2
  • Widespread distribution: Multiple sites with characteristic FDE lesions plus bullae formation
  • Significant morbidity: ICU admission required in 19.9% of cases, with mortality of 15.2% (particularly in elderly patients) 2
  • Post-inflammatory hyperpigmentation: Occurs in 54.3% of cases 2

Common Causative Agents

The most frequently implicated drugs for bullous FDE are:

  1. NSAIDs (48.7%) - particularly oxicam derivatives (meloxicam, piroxicam), acetic acid derivatives (diclofenac), and propionic acid derivatives 3, 2
  2. Antibiotics (30.9%) - especially trimethoprim-sulfamethoxazole (27.9%) and tetracyclines (20.9%) 2, 1
  3. Acetaminophen/Paracetamol 3, 4

A critical clinical pitfall: NSAIDs are available over-the-counter in many countries, making them a particularly common and underrecognized cause of GBFDE 2.

Distinguishing Features from Other Blistering Eruptions

While GBFDE shares some features with Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN), important differences exist:

  • Mucosal involvement occurs but NO ocular mucosa involvement in GBFDE 2
  • Internal organ involvement is uncommon in GBFDE 2
  • Recurrence at the same sites is pathognomonic for FDE 5
  • Shorter latency period compared to most severe cutaneous adverse reactions 2

Management Approach

Immediate permanent discontinuation of the offending drug is essential 5. Treatment includes:

  • Systemic corticosteroids (used in 50.6% of cases) 2
  • Topical corticosteroids (22.4% of cases) 2
  • Antihistamines for symptomatic relief 5
  • ICU monitoring for severe cases with extensive involvement 2

Cross-reactivity within the same NSAID chemical class is well-described 3, 4, so avoidance of the entire class is recommended for severe reactions. The 2022 practice parameter explicitly states that for severe delayed hypersensitivity reactions like FDE, avoidance without rechallenge within that class is recommended due to unpredictable recurrence risk 3.

Diagnostic Considerations

Diagnosis relies primarily on:

  • Clinical history and recurrence pattern (56.1% of cases diagnosed clinically) 1
  • Lesional or general patch testing (variable sensitivity) 3
  • Oral provocation testing when further confirmation needed 1

The median time to resolution is 11 days (IQR 8-17 days), but residual hyperpigmentation is common and persistent 2, 5.

References

Research

Male genital fixed drug eruption: a systematic review.

Clinical and experimental dermatology, 2026

Research

Generalized Bullous Fixed Drug Eruption: A Systematic Review.

The journal of allergy and clinical immunology. In practice, 2026

Guideline

drug allergy: a 2022 practice parameter update.

Journal of Allergy and Clinical Immunology, 2022

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.